Advertisement
Screener

Shattuck Labs, Inc. (STTK) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

Shattuck Labs, Inc. Stock-Based Compensation

Shattuck Labs, Inc. (STTK) reported Stock-Based Compensation of $5.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-08-11

  • Shattuck Labs, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.73M, a 44.60% increase year-over-year.
  • Shattuck Labs, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.42M, a 40.33% increase year-over-year.
  • Shattuck Labs, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.61M, a 13.19% decline year-over-year.
  • Shattuck Labs, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.78M, a 30.44% decline year-over-year.
  • Shattuck Labs, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $7.00M, a 26.72% decline from fiscal 2024.
  • Shattuck Labs, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $9.55M, a 37.57% increase from fiscal 2023.
  • Shattuck Labs, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $6.94M, a 7.38% increase from fiscal 2022.
  • Shattuck Labs, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $6.46M, a 18.20% increase from fiscal 2021.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 12 month
2026-06-30$2.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11
$5.15M
10-Q · filed 2026-08-11
$6.75M
derived: sum of 3 quarters · filed 2026-08-11
$8.53M
derived: sum of 4 quarters · filed 2026-08-11
2026-03-31$2.42M
10-Q · filed 2026-05-07
$4.02M
derived: sum of 2 quarters · filed 2026-05-07
$5.80M
derived: sum of 3 quarters · filed 2026-05-07
$7.69M
derived: sum of 4 quarters · filed 2026-08-11
2025-12-31$1.61M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
$3.38M
derived: sum of 2 quarters · filed 2026-03-05
$5.27M
derived: sum of 3 quarters · filed 2026-08-11
$7.00M
10-K · filed 2026-03-05
2025-09-30$1.78M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$3.67M
derived: sum of 2 quarters · filed 2026-08-11
$5.39M
10-Q · filed 2025-11-06
$7.24M
derived: sum of 4 quarters · filed 2026-08-11
2025-06-30$1.89M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11
$3.61M
10-Q · filed 2026-08-11
$5.46M
derived: sum of 3 quarters · filed 2026-08-11
$8.02M
derived: sum of 4 quarters · filed 2026-08-11
2025-03-31$1.72M
10-Q · filed 2026-05-07
$3.57M
derived: sum of 2 quarters · filed 2026-05-07
$6.13M
derived: sum of 3 quarters · filed 2026-05-07
$8.79M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$1.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
$4.41M
derived: sum of 2 quarters · filed 2026-03-05
$7.07M
derived: sum of 3 quarters · filed 2026-03-05
$9.55M
10-K · filed 2026-03-05
2024-09-30$2.56M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$5.22M
derived: sum of 2 quarters · filed 2025-11-06
$7.70M
10-Q · filed 2025-11-06
$9.34M
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30$2.67M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
$5.14M
10-Q · filed 2025-08-14
$6.78M
derived: sum of 3 quarters · filed 2025-08-14
$8.54M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$2.48M
10-Q · filed 2025-05-01
$4.12M
derived: sum of 2 quarters · filed 2025-05-01
$5.88M
derived: sum of 3 quarters · filed 2025-05-01
$7.73M
derived: sum of 4 quarters · filed 2025-05-01
2023-12-31$1.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27
$3.40M
derived: sum of 2 quarters · filed 2025-03-27
$5.26M
derived: sum of 3 quarters · filed 2025-03-27
$6.94M
10-K · filed 2025-03-27
2023-09-30$1.76M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$3.62M
derived: sum of 2 quarters · filed 2024-11-14
$5.30M
10-Q · filed 2024-11-14
$6.99M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$1.85M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
$3.54M
10-Q · filed 2024-08-01
$5.23M
derived: sum of 3 quarters · filed 2024-08-01
$6.95M
derived: sum of 4 quarters · filed 2024-08-01
2023-03-31$1.68M
10-Q · filed 2024-05-02
$3.38M
derived: sum of 2 quarters · filed 2024-05-02
$5.10M
derived: sum of 3 quarters · filed 2024-05-02
$6.63M
derived: sum of 4 quarters · filed 2024-05-02
2022-12-31$1.69M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$3.42M
derived: sum of 2 quarters · filed 2024-02-29
$4.95M
derived: sum of 3 quarters · filed 2024-02-29
$6.46M
10-K · filed 2024-02-29
2022-09-30$1.72M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$3.26M
derived: sum of 2 quarters · filed 2023-11-09
$4.77M
10-Q · filed 2023-11-09
$5.99M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30$1.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
$3.05M
10-Q · filed 2023-08-10
$4.26M
derived: sum of 3 quarters · filed 2023-08-10
$5.61M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$1.51M
10-Q · filed 2023-05-09
$2.73M
derived: sum of 2 quarters · filed 2023-05-09
$4.07M
derived: sum of 3 quarters · filed 2023-05-09
$5.80M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31$1.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23
$2.56M
derived: sum of 2 quarters · filed 2023-02-23
$4.29M
derived: sum of 3 quarters · filed 2023-02-23
$5.47M
10-K · filed 2023-02-23
2021-09-30$1.34M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
$3.07M
derived: sum of 2 quarters · filed 2022-11-09
$4.25M
10-Q · filed 2022-11-09
$4.89M
derived: sum of 4 quarters · filed 2022-11-09
2021-06-30$1.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
$2.91M
10-Q · filed 2022-08-11
$3.54M
derived: sum of 3 quarters · filed 2022-08-11
$3.86M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31$1.18M
10-Q · filed 2022-05-12
$1.82M
derived: sum of 2 quarters · filed 2022-05-12
$2.13M
derived: sum of 3 quarters · filed 2022-05-12
$2.27M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31$637.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15
$949.00K
derived: sum of 2 quarters · filed 2022-03-15
$1.09M
derived: sum of 3 quarters · filed 2022-03-15
$1.27M
10-K · filed 2022-03-15
2020-09-30$312.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
$455.00K
derived: sum of 2 quarters · filed 2021-11-09
$629.00K
10-Q · filed 2021-11-09
$793.00K
derived: sum of 4 quarters · filed 2021-11-09
2020-06-30$143.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
$317.00K
10-Q · filed 2021-08-12
$481.00K
derived: sum of 3 quarters · filed 2021-08-12
2020-03-31$174.00K
10-Q · filed 2021-05-10
$338.00K
derived: sum of 2 quarters · filed 2021-05-10
2019-12-31$164.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16
$461.00K
10-K · filed 2021-03-16
2019-09-30$297.00K
10-Q · filed 2020-11-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Neurogene Inc. (NGNE)$0.625B-4.46
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
CorMedix Inc. (CRMD)United States$0.605B3.25
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
Monopar Therapeutics (MNPR)United States$0.598B-34.82
Altimmune, Inc. (ALT)United States$0.593B-6.43
Climb Bio, Inc. (CLYM)United States$0.683B-13.03